Dabigatran (Pradaxa)

Active ingredient: Dabigatran
Brand name: Pradaxa

Dabigatran (Pradaxa) is an anticoagulant, used to help prevent problems caused by harmful blood clots, such as stroke. Anticoagulants are a type of anti-clotting medicine.

Dabigatran is a relatively new medicine taken in a capsule. It can be used by:

Pradaxa is available in capsules. As with other anti-clotting medicines (anticoagulant and antiplatelet medicines), there is a risk of bleeding as a side effect with dabigatran.

Find out more about:

 

Related information - dabigatran etexilate

Audience:
       

(Medicine)
09 Dec 2014 Fish oil is generally well tolerated, with few side effects. However, it can interfere with blood clotting at high doses.
(Medicine)
09 Sep 2014 Pradaxa Capsules is a brand of medicine containing the active ingredient dabigatran etexilate. Find out about side effects, who can take it and who shouldn’t use Pradaxa Capsules by reading the latest Australian consumer medicine information, plus tips on how to use medicines wisely and safely.
(Consumer publication)
11 Aug 2014 Stopping dabigatran suddenly is dangerous, and could put you at risk of blood clots, leading to a stroke. Talk to your doctor about the risks and benefits in your particular situation before making any decision about stopping dabigatran.
For health professionals (Health professional publication)
11 Aug 2014 Data suggesting variation in plasma concentration of dabigatran (Pradaxa) affects clinical outcomes contradicts key marketing claims. These data imply that, like warfarin, close monitoring would optimise dabigatran treatment. Does this change practice?
(Media release)
06 Aug 2014 With anticoagulant medicine dabigatran (brand name Pradaxa) in the news this week following reports that safety information about the medicine had been withheld by the manufacturer, NPS MedicineWise is reminding people not to stop taking it without talking to their doctor.
For health professionals (Medicine)
08 May 2014 The vitamin K antagonist warfarin and the newer oral anticoagulants dabigatran and rivaroxaban are approved treatments for stroke prevention in people with non-valvular atrial fibrillation (AF), but dabigatran and rivaroxaban are not PBS listed for this indication. Read about which people with non-valvular AF need anticoagulation and the role of these different medicines.
For health professionals (Health professional publication)
13 Mar 2014 The vitamin K antagonist warfarin can be used for the prevention and treatment of venous thromboembolism (VTE). The newer oral anticoagulants dabigatran, rivaroxaban and apixaban are all PBS subsidised for the prevention of VTE in patients undergoing total hip replacement or total knee replacement. Rivaroxaban is also PBS subsidised for treatment of acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism and prevention of recurrent VTE. Read about the place in therapy of these medicines.
(Consumer publication)
30 Sep 2013 Dabigatran is a medicine that is used to help prevent a stroke in people with a condition called atrial fibrillation. People with atrial fibrillation are more likely to develop a blood clot in their heart. The blood clot can then move to the brain and cause a stroke.
(Media release)
01 Sep 2013 NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 – and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose.
(Media release)
01 Sep 2013 NPS MedicineWise is reiterating safety messages around the newer anticoagulant medicines dabigatran (brand name Pradaxa) and apixaban (Eliquis) with their PBS listing for preventing stroke on 1 September 2013. The safety messages also apply for rivaroxaban (Xarelto) which was PBS-listed last month.